This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Buyside Predictions for 2012

BOSTON ( TheStreet) -- Gilead Sciences (GILD - Get Report) is the most loved biotech stock; Amgen (AMGN) the most hated. New drug launches by Amylin Pharmaceuticals (AMLN) and Regeneron Pharmaceuticals (REGN - Get Report) will blow. Dendreon (DNDN) is in for another rough year.

These are some of the thoughts and predictions of biotech's buyside investors for 2012, compiled by ISI Group analyst Mark Schoenebaum. His survey, completed by 266 institutional investors, isn't exactly scientific, but it does provide an interesting window into the minds of Wall Street's biotech crowd.

When asked to name their favorite biotech stock for 2012, 12% of investors picked Gilead Sciences, followed by Celgene (CELG - Get Report) with around 8% of the popular vote. Biogen Idec (BIIB), Alexion Pharmaceuticals (ALXN) and Vertex Pharmaceuticals (VRTX - Get Report) round out the top five faves.

Amgen was chosen as the least favorite biotech stock for 2012 by 12% of investors in the ISI Group-Schoenebaum survey. Gilead was second with a bit less than 8% of the vote, which likely reflects the love-hate thing investors have with the $11 billion Pharmasset (VRUS) acquisition. Celgene, Dendreon and Biogen Idec ranked 3-5 on the hated list.

No surprise seeing Dendreon land on list of bio-hazards given Provenge's epic fail last year. Investors aren't enthused about the prospect of a turnaround in 2012 either: 50% forecast Provenge will miss 2012 sales expectations. The other 50% split almost evenly between Provenge meeting and beating expectations this year.

Investor attitudes towards all drug launches seems surly, a continuation of the "short the launch" trend firmly established last year as a winning trading strategy. Forty-one percent of investors predict Regeneron's Eylea launch will fail to meet expectations, with 32% saying the launch will meet sales forecasts and 27% taking the optimistic "beat" line.

Amylin's looming Bydureon diabetes launch is likewise viewed with pessimism. Half the respondents predict a miss, with 29% and 22% forecasting "meet" and "beat," respectively.

The only faint glimmer of optimism about drug launches in Schoenebaum's survey comes from Human Genome Sciences (HGSI), where 42% of investors believe the lupus drug Benlysta can meet consensus sales expectations for 2012. Of course, Human Genome so badly failed with the Benlysta launch last year that the stock already bakes in a ton of negativity.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
DNDN $0.06 -6.02%
CELG $117.60 0.00%
GILD $99.51 0.00%
ONTY $2.70 0.00%
REGN $526.83 0.00%


Chart of I:DJI
DOW 17,131.86 +47.37 0.28%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,838.6430 +8.1730 0.17%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs